Generic Name and Formulations:
Desirudin 15mg/vial; pwd for SC inj after reconstitution; preservative-free; diluent contains mannitol.
Bausch Health Companies Inc.
Indications for IPRIVASK:
DVT prophylaxis in patients undergoing hip replacement surgery.
Not interchangeable with other hirudins. Give by SC inj, preferably in abdomen or thigh. 15mg every 12hrs starting up to 5–15min before surgery (after induction of regional block anesthesia, if used); may continue for 9–12 days post-op. Renal impairment (CrCl<60mL/min): reduce dose (see full labeling).
Traumatic or repeated neuraxial puncture. Post-op indwelling epidural catheter (place catheter before starting therapy and remove when desirudin effect is low). Hemorrhagic stroke. Recent surgery or biopsy. Diabetic retinopathy. Severe uncontrolled hypertension. Recent GI or pulmonary bleeding. Bacterial endocarditis. Renal impairment: monitor aPTT and serum creatinine closely. Hepatic impairment. Monitor for neurological impairment (may indicate spinal/epidural hematoma). Pregnancy (Cat.C). Nursing mothers.
Direct thrombin inhibitor (recombinant hirudin).
Concomitant heparins (fractionated or unfractionated): not recommended. Concomitant NSAIDs, platelet inhibitors, other anticoagulants: increased risk of bleeding, neuraxial hematoma with epidural catheters; discontinue these and others that increase bleeding risk (eg, glucocorticoids, Dextran 40) before starting desirudin. Caution with drugs that affect platelets (eg, salicylates, ticlopidine, clopidogrel, abciximab, gp IIb/IIIa antagonists). Switching to or from coumadin: monitor closely.
Bleeding, inj site reaction/mass, nausea, anaphylaxis, antibody formation.
Single-use vials—10 (w. diluent, supplies)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline